4'-Isobutyl-4-(trifluoromethyl)biphenyl | 1261585-45-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4'-Isobutyl-4-(trifluoromethyl)biphenyl
• 英文别名: 1-(2-methylpropyl)-4-[4-(trifluoromethyl)phenyl]benzene
• CAS: 1261585-45-8
• 化学式: C₁₇H₁₇F₃
• 分子量: 278.31
• InChiKey: QXVSVSSKQMIIHF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  3

文献信息

• Alkylamino, arylamino, and sulfonamido cyclopentyl amide modulators of chemokine receptor activity
  申请人：Goble D. Stephen

  公开号：US20070117797A1

  公开（公告）日：2007-05-24

  Compounds of the formula (I) which are modulators of chemokine receptor activity useful in the prevention or treatment of certain inflammatory and immunoregulatory disorders and diseases, allergic diseases, atopic conditions including allergic rhinitis, dermatitis, conjunctivitis, and asthma, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis, and pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which chemokine receptors are involved.

  公式(I)的化合物是化学趋化因子受体活性调节剂，对预防或治疗某些炎症和免疫调节性疾病和疾病、过敏性疾病、包括过敏性鼻炎、皮炎、结膜炎和哮喘等特应性疾病，以及风湿性关节炎和动脉粥样硬化等自身免疫病理学，以及包含这些化合物的药物组合物，以及这些化合物和组合物在涉及化学趋化因子受体的疾病的预防或治疗中的用途。
• [EN] RADIOLABELED DARAPLADIB AND ANALOGS THEREOF AND THEIR USE AS IMAGING COMPOUNDS<br/>[FR] DARAPLADIB RADIOMARQUÉ, SES ANALOGUES ET LEUR UTILISATION EN TANT QUE COMPOSÉS D'IMAGERIE
  申请人：INST NAT SANTE RECH MED

  公开号：WO2019063634A1

  公开（公告）日：2019-04-04

  The present inventors have developed new radiolabeled Darapladib and analogs thereof which can be used for the specific detection of vulnerable atherosclerotic plaques by targeting lipoprotein-associated phospholipase A2 (Lp-PLA2) which is a biomarker of choice concerning inflammation and atherosclerosis progression. Thus, the present invention relates to radiolabeled Darapladib and analogs thereof and their use as imaging compounds.

  目前的发明者已经开发出新的放射标记的达拉普利德及其类似物，可以通过靶向脂蛋白相关磷脂酶A2（Lp-PLA2）用于特异性检测易受损动脉粥样硬化斑块，该酶是关于炎症和动脉粥样硬化进展的首选生物标志物。因此，本发明涉及放射标记的达拉普利德及其类似物以及它们作为成像化合物的用途。
• RADIOLABELED DARAPLADIB, ANALOGS THEREOF AND THEIR USE AS IMAGING COMPOUNDS
  申请人：INSERM (Institut National de la Santé et de la Recherche Médicale)

  公开号：EP3687980B1

  公开（公告）日：2022-01-19
• COMPOUNDS
  申请人：New Pharma Licence Holdings Limited

  公开号：US20180030092A1

  公开（公告）日：2018-02-01

  The present invention provides a compound of formula (I), and its use in methods of treatment, including the treatment of bacterial infections. Methods for the preparation of the compound of formula (I) are also provided. The compound of formula (I) has the structure shown below, where —R 6 and —R 7 are each together with the carbonyl group and nitrogen alpha to the carbon to which it is attached an amino acid residue, except that R6 together with the carbonyl group and nitrogen alpha to the carbon to which it is attached is not a phenylalanine, leucine or valine residue and/or —R 7 together with the carbonyl group and nitrogen alpha to the carbon to which it is attached is not a leucine, iso-leucine, phenylalanine, threonine, valine or nor-valine residue, and —T, A 1 , A 2 , A 3 and —R 10 are as discussed in the application:
• BICYCLIC IMIDAZOLO DERIVATIVE
  申请人：Sumitomo Dainippon Pharma Co., Ltd.

  公开号：US20180044343A1

  公开（公告）日：2018-02-15

  Disclosed are compounds, having the following structure, useful as inhibitors of Phosphodiesterase 1 (PDE1), compositions comprising the compounds, and methods of using the same.